Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Clinical Study of MK-4716 in People With Certain Solid Tumors
2025-522495-84-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2 trial of MK-4716 in non-small cell lung cancer (NSCLC) and Nonhematologic neoplasms, sponsored by Merck & Co. Planned start Jan 2026; status: authorised.
02
Drugs
MK-4716
03
Conditions
non-small cell lung cancer (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on 2025-522495-84-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522495-84-00.